Olaparib for Metastatic Castration-Resistant Prostate Cancer
In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 2,067
- Institution
- AstraZeneca (United States)
External Links
Identifiers
- ORCID
- 0009-0008-0993-2783
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.